Abstract:Background: Lactate dehydrogenase A (LDHA) plays a crucial role in the final step of anaerobic glycolysis, converting L-lactate and NAD+ to pyruvate and nicotinamide adenine dinucleotide (NADH). Its high expression has been linked to tumorigenesis and patient survival in various human cancers. However, the full implications of LDHA's role and its correlation with clinicopathological features in pancreatic adenocarcinoma (PAAD) remain to be fully understood. This study was thus conducted to elucidate the specific functions of LDHA in PAAD, with the aim of providing more robust evidence for clinical diagnosis and treatment. Methods: In an extensive systems analysis, we searched through numerous databases, including The Cancer Genome Atlas (TCGA) and Oncomine. Our objective was to clarify the clinical implications and functional role of LDHA in PAAD. Bioinformatics was used to identify the biological function of LDHA expression and its correlation with tumor immune status. Results: Our analysis revealed that the LDHA gene is overexpressed in PAAD and that this upregulation was associated with a worse patient prognosis. Through gene set enrichment analysis, we found that LDHA's influence on PAAD is linked to signaling pathways involving Kirsten rat sarcoma viral oncogene homolog (K-Ras), transforming growth factor-β (TGF-β), and hypoxia inducible factor-1 (HIF-1). Mutation of K-Ras could upregulate its own expression and was positively correlated with LDHA expression. Moreover, our data demonstrated that LDHA expression was linked to immune infiltration and poor prognosis in PAAD, indicating its role in disease pathogenesis. Overexpression of LDHA may suppress tumor immunity, suggesting it as a potential target for the diagnosis and treatment of PAAD, thus providing new insights into managing this aggressive cancer. Conclusions: Overall, our results showed that LDHA as a prognostic biomarker could serve as a novel target for future PAAD immunotherapy.

Lactate dehydrogenase A is implicated in the pathogenesis of B‐cell lymphoma through regulation of the FER signaling pathway

The metabolic role of lactate dehydrogenase in the growth of diffuse large B cell lymphoma

Knockdown of LDHA Inhibits Growth and EMT of Glioma Cells

LDHA: The Obstacle to T cell responses against tumor

Targeting lactate dehydrogenase A ( LDHA ) exerts antileukemic effects on T‐cell acute lymphoblastic leukemia

LDHA as a predictive biomarker and its association with the infiltration of immune cells in pancreatic adenocarcinoma

LDHA as a regulator of T cell fate and its mechanisms in disease

Lactate dehydrogenase A is a diagnostic biomarker associated with immune infiltration, m6A modification and ferroptosis in endometrial cancer

Targeting lactate dehydrogenase a improves radiotherapy efficacy in non-small cell lung cancer: from bedside to bench

LDHA Promotes Tumor Metastasis by Facilitating Epithelial-Mesenchymal Transition in Renal Cell Carcinoma

Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma

Lactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy

Lactate dehydrogenase a in cancer: A promising target for diagnosis and therapy

[Significance of Expression and Promoter Methylation of LITAF Gene in B-cell Lymphoma].

Knockdown Of Lactate Dehydrogenase A Suppresses Tumor Growth And Metastasis Of Human Hepatocellular Carcinoma

LDHA is Necessary for the Tumorigenicity of Esophageal Squamous Cell Carcinoma.

Targeting ZDHHC21/FASN axis for the treatment of diffuse large B-cell lymphoma

Identifying the critical oncogenic mechanism of LDHA based on a prognostic model of T-cell synthetic drivers

Lactate dehydrogenase A regulates tumor-macrophage symbiosis to promote glioblastoma progression

Inhibition of LDHA suppresses tumor progression in prostate cancer

Lactate Dehydrogenase-A (LDH-A) Preserves Cancer Stemness and Recruitment of Tumor-Associated Macrophages to Promote Breast Cancer Progression